A phase I study of rhC1INH in which the drug was administered to 12 asymptomatic HAE patients at doses ranging from 6.25 to 100 U/kg [71] demonstrated a rapid increase in functional plasma C1INH activity and a corresponding fall in C4 activation, followed by a slower increase in C4 levels. This evidence concerns the gene C4A and hereditary angioedema.